Novavax (NVAX) has an average broker rating of 1.4, which is interpreted as a Strong Buy, as rated by 5 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell.
Novavax (NVAX) : The most positive equity analysts on Novavax (NVAX) expects the shares to touch $17, whereas, the least positive believes that the stock will trade at $6 in the short term. The company is covered by 5 Wall Street Brokerage Firms. The average price target for shares are $12.98 with an expected fluctuation of $4.24 from the mean.
Shares of Novavax, Inc. rose by 0.27% in the last five trading days and 1.37% for the last 4 weeks. Novavax, Inc. is up 34.55% in the last 3-month period. Year-to-Date the stock performance stands at -11.8%. Novavax (NASDAQ:NVAX): stock turned positive on Tuesday. Though the stock opened at $7.29, the bulls momentum made the stock top out at $7.47 level for the day. The stock recorded a low of $7.27 and closed the trading day at $7.4, in the green by 2.35%. The total traded volume for the day was 2,684,007. The stock had closed at $7.23 in the previous days trading.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).